HCW Biologics Inc. (HCWB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.96

From 52W high−93.61%

Volume87460.00

Market cap$3.43M

P/E (TTM)—

P/S (TTM)0.5x

Div yield—

Key dataSep 18, 2026

Open

$1.96

From 52W high

−93.61%

Volume

87460.00

Market cap

$3.43M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

P/E (TTM)

—

RSI (14)

37.4

MomentumView details →

1D Return

−4.10%

YTD Return

−63.40%

SummaryUpdated Jun 1, 2026

HCW Biologics Inc. (NASDAQ:HCWB) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Miramar, Florida. The company went public in July 2021 and focuses on developing novel immunotherapies targeting chronic, low-grade inflammation and age-related diseases. HCW Biologics operates in the highly specialized field of cancer immunotherapy and autoimmune disease treatment, with a pipeline of experimental drugs in various stages of development from preclinical research to Phase II clinical trials.

Ask drillr about HCW Biologics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.2x

EV/Sales

1.4x

P/S (TTM)

0.5x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

95.91%

Net Margin

−73.22%

EBITDA Margin

−63.56%

ROE (TTM)

−66.26%

ROA (TTM)

−18.39%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+707.02%

EPS YoY

−31.43%

FCF YoY

+4.49%

Revenue CAGR 3Y

−79.94%

EPS CAGR 3Y

—

EBITDA YoY

+46.73%

MomentumView details →

1D Return

−4.10%

YTD Return

−63.40%

1Y Return

−91.61%

RSI (14)

37.4

vs 50D SMA

−28.99%

vs 200D SMA

−59.74%

Capital & dividendView details →

Debt/Equity

0.88x

Current Ratio

0.06x

Quick Ratio

0.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$11.58

EPS Surprise

−484.85%

Beats (12Q)

2/12

Next Q EPS Est

−$1.08

Avg Surprise (4Q)

−185.43%

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

6.72M

Net Income (TTM)

−4.92M

Op. CF (TTM)

−12.14M

Next earningsNov 12, 2026 →

Latest newsMore news →

HCW Biologics signed an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent to support the production of highly functional human CAR-T cells.12d ago

HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata.18d ago

Similar companies

XORTX Therapeutics Inc.XRTX 60 Degrees Pharmaceuticals, Inc.SXTP GeoVax Labs, Inc.GOVX Aptevo Therapeutics Inc.APVO Silo Pharma, Inc.SILO Revelation Biosciences, Inc.REVB Find similar companies →

Latest newsMore news →

HCW Biologics signed an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent to support the production of highly functional human CAR-T cells.12d ago HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata.18d ago HCW Biologics announced positive preliminary human data readout for its Phase 1 clinical trial of HCW9302 in alopecia areata.96d ago